kidrolase
cts ltd - asparaginase - powder for solution for injection - asparaginase 10000 iu/vial - asparaginase - asparaginase - acute lymphoblastic leukemia, acute myeloblastic leukemia.
kidrolase powder for solution
jazz pharmaceuticals france sas - asparaginase - powder for solution - 10000unit - asparaginase 10000unit - antineoplastic agents
erwinase 10,000unit powder for solution for injection vials
porton biopharma ltd - crisantaspase - powder for solution for injection - 10000unit
spectrila 10,000unit powder for concentrate for solution for infusion vials
medac uk - asparaginase - powder for solution for infusion - 10000unit
erwinase 10 000 u powder for solution for injection/infusion
porton biopharma limited - crisantaspase - powder for solution for injection/infusion - 10,000 unit(s) - asparaginase
enrylaze
jazz pharmaceuticals ireland limited - crisantaspase - precursor cell lymphoblastic leukemia-lymphoma - antineoplastic agents - enrylaze is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukaemia (all) and lymphoblastic lymphoma (lbl) in adult and paediatric patients (1 month and older) who developed hypersensitivity or silent inactivation to e. coli-derived asparaginase.
erwinase 10,000 units. powder for solution for injection
jazz pharmaceuticals france sas - cristanspase - powder for solution for injection - 10000 international unit(s) - other antineoplastic agents; asparaginase
leunase for injection 10000 iuvial
kyowa kirin asia pacific pte. ltd. - l-asparaginase - injection, powder, for solution - 10000 iu/vial - l-asparaginase 10000 iu/vial
asparaginase 10000 u medac
medac gesellschaft fur klinische spezialpräparate mbh theaterstr. 6 22880 wedel, germany - l, asparaginase - powder for solution for injection - l-asparaginase 10000 iu - antineoplastic agents
spectrila
medac gesellschaft fuer klinische spezialpraeparate mbh - asparaginase - precursor cell lymphoblastic leukemia-lymphoma - antineoplastic agents - spectrila is indicated as a component of antineoplastic combination therapy for the treatment of acute lymphoblastic leukaemia (all) in paediatric patients from birth to 18 years and adults.